Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases-Reference-Cited by-同舟云学术

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

Published:2022-02-27 Issue:4 Volume:27 Page:294-300
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:Respirology

Author:

Brown Kevin K.¹^ORCID,Inoue Yoshikazu²^ORCID,Flaherty Kevin R.³,Martinez Fernando J.⁴,Cottin Vincent⁵^ORCID,Bonella Francesco⁶^ORCID,Cerri Stefania⁷,Danoff Sonye K.⁸,Jouneau Stephane⁹^ORCID,Goeldner Rainer‐Georg¹⁰,Schmidt Martin¹¹,Stowasser Susanne¹²,Schlenker‐Herceg Rozsa¹³,Wells Athol U.¹⁴^ORCID

Affiliation:

1. Department of Medicine National Jewish Health Denver Colorado USA

2. Clinical Research Center National Hospital Organization Kinki‐Chuo Chest Medical Center Sakai City Japan

3. Division of Pulmonary and Critical Care Medicine University of Michigan Ann Arbor Michigan USA

4. Weill Cornell Medicine New York New York USA

5. National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon Claude Bernard University Lyon 1 Lyon France

6. Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Ruhrlandklinik University Hospital University of Duisburg‐Essen Essen Germany

7. Center for Rare Lung Disease Azienda Ospedaliero‐Universitaria Policlinico di Modena Modena Italy

8. Johns Hopkins Medicine Baltimore Maryland USA

9. Department of Respiratory Medicine Competences Centre for Rare Pulmonary Diseases, CHU Rennes, IRSET UMR 1085, Univ Rennes Rennes France

10. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

11. Boehringer Ingelheim Pharma GmbH Ingelheim am Rhein Germany

12. Boehringer Ingelheim International GmbH Ingelheim am Rhein Germany

13. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield Connecticut USA

14. National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute Imperial College London UK

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14231

Reference33 articles.

1. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

2. What's in a name? That which we call IPF, by any other name would act the same

3. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

4. Spectrum of Fibrotic Lung Diseases

5. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypercapnia and lung function parameters in chronic obstructive pulmonary disease;BMC Pulmonary Medicine;2024-07-16

2. Computed tomography machine learning classifier correlates with mortality in interstitial lung disease;Respiratory Investigation;2024-07

3. Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease;Clinical Rheumatology;2024-06-19

4. Machine learning classifier is associated with mortality in interstitial lung disease: a retrospective validation study leveraging registry data;BMC Pulmonary Medicine;2024-05-23

5. Treatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey;2024-03-05